Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647317 | 0.92 | HSP90AA1 (0.52) | HSP90AA1HSD17B10GLAMAPTL3MBTL1 | |
| SCHEMBL644517 | 0.91 | HSP90AA1 (0.49) | HSP90AA1HSD17B10GLAMAPTL3MBTL1 | |
| SCHEMBL646611 | 0.90 | HSP90AA1 (0.41) | HSP90AA1HSD17B10HSP90AB1 | |
| SCHEMBL644249 | 0.90 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL645783 | 0.87 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1MAPTKMT2AMEN1 | |
| SCHEMBL646963 | 0.86 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL644537 | 0.85 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL646952 | 0.85 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1MAPT | |
| SCHEMBL644540 | 0.84 | HSP90AA1 (0.43) | HSP90AA1HSD17B10HSP90AB1 | |
| SCHEMBL4938769 | 0.84 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023922-B1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GMBH (DE) | 2012-07-11 | — | — | EP | claimed |
| US-8119795-B2 | Triazole derivatives II | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | claimed |
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-2023922-B1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSD17B10 1432/4885HSP90AB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.